The I-Score Study: Developing a New Patient-Reported Tool for the Routine HIV Care of Patients on Antiretroviral Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-30

Study Completion Date

2021-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this Canada-France study is to develop and validate a multidimensional patient-reported measure of perceived barriers to antiretroviral therapy adherence for HIV-positive patients undergoing treatment that will be theoretically founded, easy to use and helpful to clinicians in their medical decision-making, in a clinical or research setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation and Monitoring of Patients With HIV Infectionn

NCT00557570

HIV

COMPLETED

Identifying Challenges to Healthy Aging in Persons With Human Immunodeficiency Virus (HIV) Age 50 and Older

NCT05858034

HIV Aging

RECRUITING NA

Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause

NCT02404792

HIV Inflammation Obesity +1 more

COMPLETED NA

A Study of HIV-Disease Development in Aging

NCT00006144

HIV Infections

COMPLETED PHASE2

Effects of Two Anti-HIV Drug Regimens on Quality of Life and Health Care Use Among SMART Study Participants

NCT00385632

HIV Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This 24-month study aims to develop and validate a theoretically founded patient-reported outcome measure for use in routine HIV care with patients on antiretroviral therapy (ART). Eight clinical sites will be involved (4 in Canada and 4 in France). The measure will centre on patients' reported barriers to ART adherence and will be adapted for administration via electronic tablet. The study has four main steps. The psychometric validation of the tool and core of the study will be conducted in Step 3. The Observational -Prospective design applies to the field test and retest phase of Step 3. The four steps are nevertheless described below.

Step 1 -Development of the measure's conceptual framework (Start: October 2015)

1. A scoping review of existing HIV-specific patient-reported outcome measures
2. A meta-ethnography of qualitative research on HIV-positive persons' reported barriers to antiretroviral therapy (ART) adherence
3. A content analysis of qualitative interviews with HIV-positive patients on ART about their perceived barriers to adherence (n = 30 patients) The meta-ethnography and content analysis will serve to develop the conceptual framework on which the tool will be based. It will not only define the tool's conceptual domain but outline its relationship to other concepts that will be verified statistically as a part of the tool's validation. Once the framework is completed, the measure will be specified and a bank of items will be generated.

Step 2 -Linguistic validation of the preliminary measure The tool's linguistic validation will involve the professional harmonization of the English and French versions and the creation of a universal French version adapted to all French sites.

Step 3 - Exploration and validation of the measure's psychometric properties

1. During the pilot phase, we will administer our measure and other measures to a small sample size (n = 80) and conduct a number of " cognitive interviews " with participants (n = 8). This will mainly help improve our measure before the field test phase (e.g., by examining missing data, incoherent responses, any problems with question comprehension).
2. The field test (n = 160) will be done with the revised measure of the pilot phase and will include exploratory and confirmatory analyses to examine, among other aspects, the correspondence between the collected data and the conceptual framework developed in Step 1. Here we will also examine the sub-dimensions of our measure and verify the concurrent (e.g., viral load, intention to adhere to ART), convergent (e.g., beliefs about antiretroviral medication) and discriminant (e.g., quality of life) validities of the tool.
3. For the retest phase, the field test participants will be recalled either 1 week or 4 weeks later for another round of data collection to assess the measure's reliability. In this phase an additional measure not included in the previous phase will be included in the questionnaire (adherence to ART). This new measure will be used to verify the predictive validity of the tool.

Step 4 -Pilot the clinical use of the instrument Here, the finalized tool will be applied in a clinical setting with a small sample of HIV-positive patients under ART (n = 24) and their clinicians (n = 8).The aim is to collect data on the tool's perceived utility from the perspective of both populations in order to provide an initial assessment of the feasibility of the tool's wider implementation.

Statistical analyses planned Statistical analyses of the quantitative pilot test phase (n = 80)

* Response coherence
* Analysis of item score distributions
* Analysis of missing data
* Principal components analyses Statistical analyses of the field test phase (n = 160)
* Exploratory analyses
* Confirmatory analyses
* Verification of the measure's convergent, discriminant and concurrent validities Statistical analyses of the retest phase (a random sample of n = 160)
* Principal components analysis and internal consistency through Cronbach's alpha in order to verify whether the factors obtained at the retest phase are the same as those obtained from the field test phase
* Descriptive statistics and multivariate analyses will be carried out in order to compare score means and to verify whether the factors associated with the I-score are the same in phases 2 and 3 Statistical analyses of the Pilot of the instrument's clinical use (n = 24 patients; n = 8 HIV clinicians)
* The statistics produced for this step of the study will be descriptive (e.g., percentages, averages) and comparative. For comparative analyses between patients and their doctors (e.g., on the tool's appreciation), tests will be adapted according to whether the variables used are continuous (e.g., t-tests) or categorical (e.g., chi-square).
* Furthermore, patient and clinician data will be analyzed with a multi-level model to examine, for example, if patient appreciation (or non-appreciation) of the tool is associated or not with differences in the clinicians' perceptions (estimation of individual and structural factors associated with appreciation or non-appreciation).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV/AIDS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be a man, woman or transgender person aged 18 years or older
* Be diagnosed HIV-1 positive
* Be treated by a combination of 2 to 3 antiretroviral drugs for at least 3 months
* Ability to speak and understand either French or English

Exclusion Criteria

* Participation in a clinical trial at the time of enrollment in this study, in some cases (to be discussed on a site-by-site basis by the scientific committee)
* Having a cognitive impairment or medical instability that prevents their use of the electronic tablet, completion of the questionnaire or participation in the interview
* Insufficient mastery of French or English to complete the questionnaires or participate in the interview
* Refusal to use the electronic tablet to fill out the questionnaire material (not relevant for the qualitative and cognitive interviews)
* Co-infection with hepatitis C and currently under treatment for it or having completed hepatitis C treatment 3 months ago or less
* Co-infection with hepatitis B and either not being treated for it or receiving a treatment for it other than one's antiretroviral therapy for HIV
* Participation in the study's Pilot phase (for the field test and retest)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Bertrand Lebouche

MD, PhD, Assistant Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bertrand Lebouché, MD PhD

Role: PRINCIPAL_INVESTIGATOR

McGill University Health Centre, Chronic Viral Illness Service, Royal Victoria Hospital - Glen Site D02.4110 - 1001 boul Décarie, Montreal, QC H4A 3J1